Abstract
It is estimated that a typical myocardial infarction results in the loss of approximately one billion functional cardiomyocytes, which are replaced by a non-contractile fibrous scar, eventually leading to heart failure. The currently available surgical, drug, and device-based therapies cannot reverse the loss of functional myocardium, which is the fundamental cause of the problem. As a result of this lack of an available medical solution, heart failure has evolved into a global epidemic. Therefore, the development of regenerative therapeutic strategies to halt the progression of ischemic heart disease to advanced heart failure has become one of the most urgent medical needs of this century. This review first addresses the extremely limited endogenous regenerative capacity of the mammalian heart, and the benefits and limitations of stem cell-based therapies for cardiac repair. Then it discusses the known roles of microRNAs after cardiac injury and the possibility of employing microRNAs to enhance cardiac regeneration.
Keywords: Cardiac progenitor cells, cardiomyocytes, cardiovascular disease, heart failure, microRNA, regeneration, stem cells, transplantation.
Mini-Reviews in Medicinal Chemistry
Title:MicroRNA Therapeutics for Cardiac Regeneration
Volume: 15 Issue: 6
Author(s): Zhiyong Lei, Joost P.G. Sluijter and Alain van Mil
Affiliation:
Keywords: Cardiac progenitor cells, cardiomyocytes, cardiovascular disease, heart failure, microRNA, regeneration, stem cells, transplantation.
Abstract: It is estimated that a typical myocardial infarction results in the loss of approximately one billion functional cardiomyocytes, which are replaced by a non-contractile fibrous scar, eventually leading to heart failure. The currently available surgical, drug, and device-based therapies cannot reverse the loss of functional myocardium, which is the fundamental cause of the problem. As a result of this lack of an available medical solution, heart failure has evolved into a global epidemic. Therefore, the development of regenerative therapeutic strategies to halt the progression of ischemic heart disease to advanced heart failure has become one of the most urgent medical needs of this century. This review first addresses the extremely limited endogenous regenerative capacity of the mammalian heart, and the benefits and limitations of stem cell-based therapies for cardiac repair. Then it discusses the known roles of microRNAs after cardiac injury and the possibility of employing microRNAs to enhance cardiac regeneration.
Export Options
About this article
Cite this article as:
Lei Zhiyong, Sluijter P.G. Joost and Mil van Alain, MicroRNA Therapeutics for Cardiac Regeneration, Mini-Reviews in Medicinal Chemistry 2015; 15 (6) . https://dx.doi.org/10.2174/1389557515666150324123913
DOI https://dx.doi.org/10.2174/1389557515666150324123913 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
p53: A Guide to Apoptosis
Current Cancer Drug Targets Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets The Pathophysiology of Uric Acid in Relation to Cardiovascular Disease
Current Cardiology Reviews Drug-Induced Hypokalaemia
Current Drug Safety Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Tissue Regeneration: From Synthetic Scaffolds to Self-Organizing Morphogenesis
Current Stem Cell Research & Therapy Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication
Current Hypertension Reviews Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?
Current Pharmaceutical Design The Na+/Ca2+ Exchanger Mediates the Effects of Oxidative Stress in Hypertension
Current Hypertension Reviews The Malignant Obesity Hypoventilation Syndrome (MOHS)
Current Respiratory Medicine Reviews Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Caspases as Drug Targets in Ischemic Organ Injury
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Targeting Interleukin (IL) 5 for Asthma and Hypereosinophilic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Therapeutic Approaches Multi-Targeting Receptor Tyrosine Kinases and G Protein-Coupled Receptors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Epidural Analgesia in the Post-Anaesthesia Care Unit
Current Drug Targets Epidemiology of Septic Acute Kidney Injury
Current Drug Targets